Gene, ethnic and gender influences predisposition of adverse drug reactions to artesunate among Malaysians

References

• Adisa R, Fakeye TO, Dike D. 2008. Evaluation of adverse drug reactions to artemisinin based combination therapy in a Nigeria University Community. Trop J Pharmaceut Res 7:937–944.
   Google Scholar
• Adjei GO, Kurtzhals JA, Rodrigues OP, Alifrangis M, Hoegberg LC, Kitcher ED, Badoe EV, Lamptey R, Goka BQ. 2008. Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: A randomized efficacy and safety trial with one year follow-up. Malar J 7:127.
   PubMed Web of Science ®Google Scholar
• Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WR. 2002. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: A randomised, multicentre trial. Lancet 359:1365–1372.
   PubMed Web of Science ®Google Scholar
• Ariyoshi N, Sawamura Y, Kamataki T. 2001. A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun 281:810–814.
   PubMed Web of Science ®Google Scholar
• Asante KP, Owusu R, Dosoo D, Awini E, Adjei G, Amenga Etego S, Chandramohan D, Owusu-Agyei S. 2009. Adherence to Artesunate-Amodiaquine Therapy for Uncomplicated Malaria in Rural Ghana: A Randomised Trial of Supervised versus Unsupervised Drug Administration. J Trop Med 2009:529583.
   Google Scholar
• Barennes H, Nagot N, Valea I, Koussoubé-Balima T, Ouedraogo A, Sanou T, Yé S. 2004. A randomized trial of amodiaquine and artesunate alone and in combination for the treatment of uncomplicated falciparum malaria in children from Burkina Faso. Trop Med Int Health 9:438–444.
   PubMed Web of Science ®Google Scholar
• Chadwick B, Waller DG, Edwards JG. 2005. Potentially hazardous drug interactions with psychotropics. Adv Psychiatr Trea 11:440–449.
   Google Scholar
• Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. 2001. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597–607.
   PubMedGoogle Scholar
• Franconi F, Brunelleschi S, Steardo L, Cuomo V. 2007. Gender differences in drug responses. Pharmacol Res 55:81–95.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. 2001. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 482:11–19.
   PubMed Web of Science ®Google Scholar
• Ju C, Uetrecht JP. 2002. Mechanism of idiosyncratic drug reactions: Reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab 3:367–377.
   PubMedGoogle Scholar
• Kwon JT, Nakajima M, Chai S, Yom YK, Kim HK, Yamazaki H, Sohn DR, Yamamoto T, Kuroiwa Y, Yokoi T. 2001. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics 11:317–323.
   PubMedGoogle Scholar
• Li XQ, Björkman A, Andersson TB, Gustafsson LL, Masimirembwa CM. 2003. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59:429–442.
   PubMed Web of Science ®Google Scholar
• Li XQ, Björkman A, Andersson TB, Ridderström M, Masimirembwa CM. 2002. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: A new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 300:399–407.
   PubMed Web of Science ®Google Scholar
• Mahavorasirikul W, Tassaneeyakul W, Satarug S, Reungweerayut R, Na-Bangchang C, Na-Bangchang K. 2009. CYP2A6 genotypes and coumarin-oxidation phenotypes in a Thai population and their relationship to tobacco smoking. Eur J Clin Pharmacol 65:377–384.
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Lapeyre-Mestre M, Bagheri H, Fooladi A. 2002. Gender differences in adverse drug reactions: Analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France. Fundam Clin Pharmacol 16:343–346.
   PubMed Web of Science ®Google Scholar
• Muthiah YD, Lee WL, Teh LK, Ong CE, Ismail R. 2005. Genetic polymorphism of CYP2C8 in three Malaysian ethnics: CYP2C8*2 and CYP2C8*3 are found in Malaysian Indians. J Clin Pharm Ther 30:487–490.
   PubMedGoogle Scholar
• Mwenifumbo JC, Lessov-Schlaggar CN, Zhou Q, Krasnow RE, Swan GE, Benowitz NL, Tyndale RF. 2008. Identification of novel CYP2A6*1B variants: The CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther 83:115–121.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H, Yamazaki H, Yamamoto T, Kuroiwa Y, Yokoi T. 2001. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 69:72–78.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yokoi T. 2005. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab Pharmacokinet 20:227–235.
   PubMedGoogle Scholar
• Navaratnam V, Ramanathan S, Wahab MS, Siew Hua G, Mansor SM, Kiechel JR, Vaillant M, Taylor WR, Olliaro P. 2009. Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers. Eur J Clin Pharmacol 65:809–821.
   PubMed Web of Science ®Google Scholar
• Newton P, Suputtamongkol Y, Teja-Isavadharm P, Pukrittayakamee S, Navaratnam V, Bates I, White N. 2000. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob Agents Chemother 44:972–977.
   PubMed Web of Science ®Google Scholar
• Nicolson TJ, Mellor HR, Roberts RR. 2010. Gender differences in drug toxicity. Trends Pharmacol Sci 31:108–114.
   PubMed Web of Science ®Google Scholar
• Orrell C, Little F, Smith P, Folb P, Taylor W, Olliaro P, Barnes KI. 2008. Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur J Clin Pharmacol 64:683–690.
   PubMed Web of Science ®Google Scholar
• Oscarson M, Gullstén H, Rautio A, Bernal ML, Sinues B, Dahl ML, Stengård JH, Pelkonen O, Raunio H, Ingelman-Sundberg M. 1998. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett 438:201–205.
   PubMed Web of Science ®Google Scholar
• Oscarson M, McLellan RA, Gullstén H, Yue QY, Lang MA, Bernal ML, Sinues B, Hirvonen A, Raunio H, Pelkonen O, Ingelman-Sundberg M. 1999a. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 448:105–110.
   PubMed Web of Science ®Google Scholar
• Oscarson M, McLellan RA, Gullstén H, Agúndez JA, Benítez J, Rautio A, Raunio H, Pelkonen O, Ingelman-Sundberg M. 1999b. Identification and characterisation of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism. FEBS Lett 460:321–327.
   PubMed Web of Science ®Google Scholar
• Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM; U.S. Acute Liver Failure Study Group. 2002. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137:947–954.
   PubMed Web of Science ®Google Scholar
• Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL. 2007. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: Implications for malaria treatment in Africa. Clin Pharmacol Ther 82:197–203.
   PubMed Web of Science ®Google Scholar
• Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M. 2001. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: Impairment of its promoter activity. Biochem Biophys Res Commun 284:455–460.
   PubMed Web of Science ®Google Scholar
• Rawlins M, Thompson J. 1977. Pathogenesis of adverse drug reactions In: Davies DM, (ed). Textbook of Adverse Drug Reactions. Oxford: Oxford University Press, pp. 10–31.
   Google Scholar
• Roden DM. 2009. Toxicology and genetics of adverse drug events. In: Robertson D, Williams GH, (eds). Clinical and Translational Science - Principles of Human Research. Massachusetts: Academic Press, pp. 339–344.
   Google Scholar
• Ruzilawati AB, Gan SH. 2010. CYP3A4 genetic polymorphism influences repaglinide’s pharmacokinetics. Pharmacology 85:357–364.
   PubMed Web of Science ®Google Scholar
• Severino G, Del Zompo M. 2004. Adverse drug reactions: Role of pharmacogenomics. Pharmacol Res 49:363–373.
   PubMed Web of Science ®Google Scholar
• Soyama A, Saito Y, Komamura K, Ueno K, Kamakura S, Ozawa S, Sawada J. 2002. Novel single nucleotide polymorphisms in the CYP2D6 gene associated with CYP2D6*2 and/or CYP2D6*10 alleles. Drug Metab Pharmacokinet 17:475–478.
   Google Scholar
• Tohkin M, Ishiguro A, Kaniwa N, Saito Y, Kurose K, Hasegawa R. 2010. Prediction of severe adverse drug reactions using pharmacogenetic biomarkers. Drug Metab Pharmacokinet 25:122–133.
   PubMedGoogle Scholar
• Tran C, Knowles SR, Liu BA, Shear NH. 1998. Gender differences in adverse drug reactions. J Clin Pharmacol 38:1003–1009.
   PubMed Web of Science ®Google Scholar
• WHO. (2001). Antimalarial drug combination therapy: Report of a WHO consultation. In: Geyer, M. (ed). WHO Technical Consultation, Vol. WHO/CDS/RBM/2001.35. Geneva: WHO.
   Google Scholar
• Yoshida R, Nakajima M, Watanabe Y, Kwon JT, Yokoi T. 2002. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol 54:511–517.
   PubMed Web of Science ®Google Scholar
• Yusof W, Gan SH. 2009a. High prevalence of CYP2A6*4 and CYP2A6*9 alleles detected among a Malaysian population. Clin Chim Acta 403:105–109.
   Google Scholar
• Yusof W, Gan SH. 2009b. Simultaneous detection of CYP2C8*2, CYP2C8*3, CYP2C8*4 and CYP2C8*5 alleles by a nested PCR method. Asia Pac J Mol Biol Biotechnol 17:39–45.
   Google Scholar
• Zopf Y, Rabe C, Neubert A, Janson C, Brune K, Hahn EG, Dormann H. 2009. Gender-based differences in drug prescription: Relation to adverse drug reactions. Pharmacology 84:333–339.
   Google Scholar